However , John Eikelboom of McMaster University , writing in a commentary in the Lancet , questioned the need for another treatment option like otamixaban . " Without safety or convenience advantages , otamixaban would need to demonstrate efficacy that is superior not only to heparin , but also to bivalirudin ( Angiomax ) , before it would be adopted for clinical use , " he wrote .